Psilocybin-Assisted Therapy for Intergenerational Trauma
Processing Intergenerational Trauma With Psilocybin-Assisted Therapy
Rachel Yehuda
100 participants
Aug 28, 2025
INTERVENTIONAL
Conditions
Summary
This is an open-label psilocybin-assisted therapy study that will examine the safety and tolerability of psilocybin-assisted therapy in the offspring of genocide survivors with mood and anxiety disorders. The study will also investigate the efficacy of psilocybin-assisted therapy in reducing symptoms such as depression, anxiety and stress, as well as changes to the psychological effects of parental exposure to genocide, and changes to psychological resilience.
Eligibility
Plain Language Summary
Simplified for easier understanding
This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
Psilocybin 25mg, capsules taken orally under the supervision of two trained study therapists
weekly integration sessions (therapy) for 6 weeks
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT06899165